Tuberous sclerosis cost-effectiveness of therapy

Jump to navigation Jump to search

Tuberous sclerosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Differentiating Tuberous sclerosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Tuberous sclerosis cost-effectiveness of therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Tuberous sclerosis cost-effectiveness of therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Tuberous sclerosis cost-effectiveness of therapy

CDC on Tuberous sclerosis cost-effectiveness of therapy

Tuberous sclerosis cost-effectiveness of therapy in the news

Blogs on Tuberous sclerosis cost-effectiveness of therapy

Directions to Hospitals Treating Tuberous sclerosis

Risk calculators and risk factors for Tuberous sclerosis cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: José Eduardo Riceto Loyola Junior, M.D.[2]

Overview

The treatment of tuberous sclerosis can be expensive, especially considering that many complications have surgical options for treatment.

Cost-effectiveness of Therapy

A study from 2016 showed that for children with TSC presenting with refractory epilepsy (defined by the persistence of seizures despite the use of 2 anti-seizure drugs), the most cost-effective measure between resective epilepsy surgery, vagus nerve stimulator implantation, ketogenic diet, and addition of a third anti-seizure drug, was the addition of a third drug into the medication regimen,[1]

References

  1. Fallah, Aria, et al. "Cost-utility analysis of competing treatment strategies for drug-resistant epilepsy in children with tuberous sclerosis complex." Epilepsy & Behavior 63 (2016): 79-88.